Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer

[1]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[2]  S. Pascolo.  Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. , 2016, European journal of pharmacology.

[3]  N. Matsumura,et al.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.

[4]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[5]  A. Farias,et al.  Chloroquine Treatment Enhances Regulatory T Cells and Reduces the Severity of Experimental Autoimmune Encephalomyelitis , 2013, PloS one.

[6]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[7]  J. Bargman,et al.  The role of antimalarial agents in the treatment of SLE and lupus nephritis , 2011, Nature Reviews Nephrology.

[8]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[9]  Hoyun Lee,et al.  Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. , 2009, European journal of pharmacology.

[10]  Q. Zhan,et al.  Blocking TLR2 Activity Attenuates Pulmonary Metastases of Tumor , 2009, PloS one.

[11]  J. Thigpen.  Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival , 2009 .

[12]  D. Alberts,et al.  Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. , 2008, Gynecologic oncology.

[13]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[14]  M. Schlitzer,et al.  Malaria Chemotherapeutics Part I: History of Antimalarial Drug Development, Currently Used Therapeutics, and Drugs in Clinical Development , 2007, ChemMedChem.

[15]  J. Sotelo,et al.  Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. , 2007, Surgical neurology.

[16]  D. Jue,et al.  Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes , 2006 .

[17]  J. Sotelo,et al.  Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme , 2006, Annals of Internal Medicine.

[18]  D. Jue,et al.  Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. , 2006, Rheumatology.

[19]  D. Accapezzato,et al.  Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo , 2005, The Journal of experimental medicine.

[20]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.